Ocrelizumab Ocrevus®
The SHIKARI® Ocrelizumab portfolio supports quantitative analysis of free ocrelizumab and quantitative measurement of antibodies to ocrelizumab in human serum or plasma.
Why Ocrelizumab is relevant to biological-drug monitoring research
Ocrelizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Ocrelizumab is a humanised IgG1 monoclonal antibody that targets CD20 on B cells and causes selective depletion of CD20-positive B-cell populations. Source ↗
Approved Indications
EMA-authorised uses include relapsing forms of multiple sclerosis and early primary progressive multiple sclerosis in defined adult patients. EMA source ↗
Infusion Peak Exposure
FDA pharmacokinetic data report peak serum concentrations following approved intravenous regimens:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Ocrelizumab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free ocrelizumab in human serum or plasma.
Quantitative ELISA for antibodies to ocrelizumab in human serum or plasma, including the assay-specific confirmation-reagent procedure.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-OCR | OCR-FD-OCR | Quantitative | Free ocrelizumab | Human serum / plasma | 10 µL | 70 min | LOD 1.56 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATOCR | OCR-QNS-OCR | Quantitative | Antibodies to ocrelizumab | Human serum / plasma | 5 µL | 140 min | LOD 0.5 µg/mL; LOQ 1 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Choose among the two assays according to the analytical output required by the study.
Ocrelizumab Literature and Product-Use Records
Planning a Ocrelizumab research study?
Matrix Biotek can help identify the appropriate Ocrelizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.